Danaher Corporation (LON: 0R2B)
London
· Delayed Price · Currency is GBP · Price in USD
245.47
+3.34 (1.38%)
Jan 22, 2025, 7:13 PM BST
Danaher Revenue
Danaher had revenue of $5.80B USD in the quarter ending September 27, 2024, with 3.09% growth. This brings the company's revenue in the last twelve months to $23.74B, up 12.92% year-over-year. In the year 2023, Danaher had annual revenue of $23.89B, down -10.33%.
Revenue (ttm)
$23.74B
Revenue Growth
+12.92%
P/S Ratio
n/a
Revenue / Employee
$376.86K
Employees
63,000
Market Cap
143.20B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 23.89B | -2.75B | -10.33% |
Dec 31, 2022 | 26.64B | 1.84B | 7.42% |
Dec 31, 2021 | 24.80B | 2.52B | 11.30% |
Dec 31, 2020 | 22.28B | 4.37B | 24.42% |
Dec 31, 2019 | 17.91B | 862.00M | 5.06% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 38.20B |
GSK plc | 31.31B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
ConvaTec Group | 1.74B |
Hikma Pharmaceuticals | 2.39B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |
Danaher News
- 7 days ago - Danaher: Transition Year Recap - Seeking Alpha
- 7 days ago - The Near-Perfect Dividend Portfolio With 10 Sleep-Well-At-Night Gems - Seeking Alpha
- 7 days ago - Danaher Corp (DHR) Unveils Advanced RUO Assays for Neurodegenerative Disease Research - GuruFocus
- 8 days ago - Beckman Coulter Introduces Cutting-Edge Research Use Only Assays for Neurodegenerative Disease Research - PRNewsWire
- 8 days ago - Danaher Corporation: Question Mark Behind The Moat And Probably Overvalued - Seeking Alpha
- 8 days ago - Danaher Corporation (DHR) 43rd Annual J.P. Morgan Healthcare Conference (Transcript) - Seeking Alpha
- 9 days ago - Danaher expects low-single digit percent revenue growth in Q4 - Seeking Alpha
- 9 days ago - Danaher CEO to Comment on Financial Performance - PRNewsWire